Home » Stocks » TCRX

TScan Therapeutics, Inc. (TCRX)

Stock Price: $9.70 USD -0.02 (-0.21%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 232.20M
Revenue (ttm) 1.09M
Net Income (ttm) -26.13M
Shares Out 23.94M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $9.70
Previous Close $9.72
Change ($) -0.02
Change (%) -0.21%
Day's Open 9.65
Day's Range 9.65 - 10.02
Day's Volume 43,818
52-Week Range 9.38 - 12.32

News

Hide News

Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T ...

1 week ago - GlobeNewsWire

TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell...

2 weeks ago - GlobeNewswire

TScan Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About TCRX

TScan Therapeutics is a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system ... [Read more...]

Industry
Biological Products
IPO Date
Jul 16, 2021
CEO
David Southwell
Employees
60
Stock Exchange
NASDAQ
Ticker Symbol
TCRX
Full Company Profile

Financial Performance

Financial Statements